Biotech Submits IND Application With FDA

Biotech Submits IND Application With FDA

By: Tomas Ronolski - News

Tuesday, May 4, 2021

An Austin-based biotech firm just announced their submission of Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initial of a Phase 1 clinical trial of Samarium-153 DOTMP (CycloSam ® ) in patients with bone cancer. Shares of QSAM Biosciences Inc. (OTCQB:QSAM) rallied on the news.

QSAM Bioscience, Inc. (f/k/a Q2Earth. Inc.) holds the worldwide license for CycloSam (Samaium-153 DOTMP), a clinical stage novel radiopharmaceutical meant to treat different types of bone cancer and related diseases. This nuclear technology uses low specific activity Samarium-153 (resulting in far less europium) and DOTMP, a chelator which is believed to eliminate off-target migration and targets high bone turn over making it an ideal agent to treat osteosarcoma, bone metastases and to perform bone marrow ablation. Sm-153 DOTMP has been cleared by the FDA under an investigator initiated IND to commence human dosing of cancer patients.

Traders were bullish on the news as shares climbed up to an early session high of $0.535/share (+27.00%) following the news. This move was welcomed by long term shareholders who have been holding on during the pullback since mid-February.

Copyright © 2021 All rights reserved. Republication or redistribution of's content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Canadian Payment Firm Jumps on Crypto-to-Fiat Bridge
Slipknot and Cannabis Company Launch Special Edition Packs
Shares of Luxury Retailer Pop on Mothers Day Sales
Most Popular
FREE Newsletter Favorites

Back to Top